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Abstract: The inverse correlation observed between Alzheimer’s disease (AD) and cancer has
prompted us to look for cholinesterase-inhibiting activity in phenothiazine derivatives that possess
anticancer properties. With the use of in silico and in vitro screening methods, our study found a
new biological activity in anticancer polycyclic, tricyclic, and tetracyclic compounds. The virtual
screening of a library of 120 ligands, which are the derivatives of azaphenothiazine, led to
the identification of 25 compounds that can act as potential inhibitors of acetylcholinesterase
(AChE) and butyrylcholinesterase (BuChE). Biological assays revealed the presence of selective
inhibitors of eeAChE (electric eel AChE) or eqBuChE (equine serum BuChE) and nonselective inhibitors
of both enzymes among the tested compounds. Their potencies against eeAChE were in a
submicromolar-to-micromolar range with IC50 values from 0.78 to 19.32 µM, while their IC50
values against eqBuChE ranged from 0.46 to 10.38 µM. The most potent among the compounds
tested was the tetracyclic derivative, 6-(4-diethylaminobut-2-ynyl)-9-methylthioquinobenzothiazine
24, which was capable of inhibiting both enzymes. 9-Fluoro-6-(1-piperidylethyl)quinobenzothiazine
23 was found to act as a selective inhibitor of eqBuChE with an IC50 value of 0.46 µM. Compounds
with such a dual antitumor and cholinesterase-inhibitory activity can be considered as a valuable
combination for the treatment of both cancer and AD prevention. The results presented in this study
might open new directions of research on the group of tricyclic phenothiazine derivatives.
Keywords: cholinesterase inhibitors; virtual screening; Alzheimer’s disease; anticancer agents;
dipyridothiazines; quinobenzothiazine
1. Introduction
Alzheimer’s disease (AD) and cancer are widespread illnesses responsible for a number of deaths
and, hence, are considered not only as a medical but also as a social and economic problem in the
modern world. The observational epidemiological data revealed an inverse correlation between the
two diseases [1–3], which led to the initiation of various studies aiming to analyze the background of
this association [4–7]. It has been found that compared to people without Alzheimer’s dementia the
risk of developing cancer is lower among patients with AD while the risk of developing AD is lower in
patients with a history of cancer [8–10]. The results of the current research indicate the link between
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the molecular mechanisms involved in various types of cancers and AD, and encourage the use of
some anticancer agents in the treatment of AD [11–14]. The knowledge and understanding gained
from these studies can be applied for developing new therapies and designing new effective drugs for
the treatment of both diseases.
AD is a progressive, complex neurodegenerative disorder that results in memory loss and
affects the cognitive functions of the brain. According to the oldest pathophysiological hypothesis,
memory impairments associated with AD are caused by the degradation and loss of cholinergic
neurons in the central nervous system (CNS) and the impairment of cholinergic neurotransmission [15].
Acetylcholinesterase (AChE, E.C.3.1.1.7) and butyrylcholinesterase (BuChE, E.C.3.1.1.8) are enzymes
belonging to the group of serine hydrolases. These enzymes can hydrolyze the acetylcholine (ACh)
neurotransmitter and some other choline esters, but to a different extent. The major role of AChE is to
catalyze the hydrolysis of ACh in cholinergic synapses, whereas the function of BuChE is less clearly
defined and it is thought to play a secondary role [16]. In addition, cholinesterases have been shown to
perform some noncholinergic functions. Both AChE and BuChE regulate neuronal development and
participate in cellular proliferation, differentiation, and adhesion by modulating the activity of other
proteins [17–19].
Increased attention has been paid to the function of AChE in CNS due to its involvement in the
pathogenesis of AD, which is the most common form of dementia. During AD, the concentration
of AChE significantly decreases. On the other hand, the level of BuChE increases, especially in the
hippocampus and temporal cortex of the brain which are the regions responsible for cognition and
behavior, and compensates for the loss of AChE [20]. Both these enzymes have also been shown to be
associated with the formation of β-amyloid (Aβ) fibrils and neurofibrillary tangles (NFTs), the two
major hallmarks of AD, as well as with the development of neuroinflammation [21]. The cholinergic
hypothesis first led to the introduction of cholinesterase inhibitors such as rivastigmine, donepezil,
and galantamine in AD therapy. Since then, many structurally diverse inhibitors of cholinesterase have
been developed, as well as the multifunctional ligands—the cholinesterase inhibitors with additional
properties that have the potential to act as anti-AD agents. Therefore, AChE and BuChE are still
considered as valuable targets in the search for new anti-AD agents.
On the other hand, the involvement of AChE in nonneuronal functions such as the regulation of
cell proliferation, differentiation, and apoptosis has suggested that it might play a role in different types
of cancers [19,22]. AChE has been found to exhibit a proapoptotic function that is independent of its
cholinergic role and is therefore believed to be involved in both tumorigenesis and neurodegenerative
diseases [23]. These indicate that AChE might serve as a potential therapeutic target in cancer
therapy [24]. Some anticancer drugs, such as doxorubicin, daunorubicin, irinotecan [25], sunitinib [26],
and Ru(II) complexes with derivatives of phenothiazine, have been shown to possess AChE-inhibitory
effects (Figure 1). Moreover, the cholinesterase-inhibitory potency is identified among different
chemical classes of anticancer compounds [27,28]. It is interesting to note that anti-AD drugs including
donepezil and galantamine also possess anticancer properties [29].
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In the present work, we focus on multifunctional ligands as potential anti AD agents among the
group of tricyclic and tetracyclic derivatives endowed with anticancer activity.
The derivatives of tricyclic dipyridothiazine and tetracyclic quinobenzothiazine displayed
varied levels of anticancer activity depending on the type of polycyclic rings and the nature of
the substituents [30–36]. They exhibited cytotoxic as well as antiproliferative action against human
peripheral blood mononuclear cells stimulated with phytohemagglutinin A and suppressed the
lipopolysaccharide-induced production of tumor necrosis factor-alpha by human whole-blood cell
cultures. In addition, the compounds that showed the highest antiproliferative activity inhibited the
growth of leukemia L-1210 and colon cancer SN-948 cell lines and actively controlled the proliferation
of glioblastoma SNB-19, melanoma C-32, lung cancer A549, colorectal cancer Caco-2, breast cancer
MCF-7 and MDA-MB231, and ductal carcinoma T47D cell lines [32,33]. Furthermore, the results of
some additional experiments, such as the analysis of gene expression, indicated the induction of
mitochondrial apoptosis in cancer cell lines [30,32,35–37].
Based on the assumption that AD and cancer have common mechanisms of formation, but differ
in the reverse of processes, we decided to evaluate the cholinesterase-inhibiting activity of a set of
compounds with confirmed antitumor potency. Therefore, in the present study, we searched for
cholinesterase inhibitors among polycyclic, tricyclic, and tetracyclic compounds using in silico and
in vitro screening methods.
2. Results and Discussion
In the first stage of the in silico screening process, we selected a previously synthesized library
of 120 ligands, which were the derivatives of azaphenothiazine. The structures of these ligands
are listed in Supplement Table S1. Most of the compounds analyzed can be assigned to one of
the following two groups: diazaphenothiazines and quinobenzothiazines. Virtual screening of
the compounds was performed based on the custom docking protocol that was described and
validated in a previous work [38]. We tested each compound against two molecular targets: AChE
in complex with bis-7-tacrine (PDB: 2CKM) and BuChE in complex with hydrolysis products (PDB:
1P0I). Tacrine and bis-7-tacrine were chosen as reference ligands due to their structural similarity with
the screened compounds. Based on the results of virtual screening, we selected potential hits from
each isomeric group of dipyridothiazines (1,6-diaza, 1,8-diaza, 2,7-diaza, and 3,6-diaza isomers) and
9-substituted quinobenzothiazine analogs (fluoro and methylthio derivatives). In both tricyclic and
tetracyclic compounds, different substituents were attached to the nitrogen atom of the thiazine system.
The values of the scoring functions achieved by the reference compounds were equal to 57.12 (tacrine)
and 111.20 (bis-7-tacrine) after docking to 2CKM complex. During docking to BuChE, score values
of 98.26 and 111.36, respectively, were reached by the compounds. The values of the evaluation
function calculated for the selected compounds were in the range of 64.32–95.78 for AChE complex
and 98.48–110.02 for BuChE complex.
The procedure resulted in the selection of 25 potential cholinesterase inhibitors. Compounds
selected through virtual screening were tested for their ability to inhibit the activity of selected biological
targets. The cholinesterase-inhibitory potency of the compounds was evaluated according to Ellman’s
method [39] using AChE obtained from E. electricus (eeAChE) and BuChE obtained from equine serum
(eqBuChE). Tacrine was used as a reference compound for this analysis. The results are presented
in Table 1. Selected data on anticancer activity for 20 tested compounds and related references are
presented in the Supplementary materials—Table S1.
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Table 1. Inhibition of AChE and BuChE by polycyclic compounds selected by virtual in silico screening.
Compound R
%
Inhibition
+/− 6 a
IC50 eeAChE
b [µM] +/−
SEM c
%
Inhibition
+/− 6
IC50 eqBuChE
d [µM] +/−
SEM
Dipyridothiazines
isomer 1,6-diaza
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isomer 1,6-
diaza
 
1 
 
45.4 ± 9.8 — 65.4 ± 3.0 5.748 ± 0.164 
2 
 
60.3 ± 8.8 8.309 ± 0.315 56.6 ± 2.4 8.942 ± 0.239 
3 13.7 ± 1.5 — 63.6 ± 2.4 9.250 ± 0.275 
4 
 
22.4 ± 1.1 — 57.0 ± 7.4 9.493 ± 0.330 
5 
 
7.3 ± 0.9 — 52.5 ± 5.9 10.080 ± 0.441 
isomer 1,8-
diaza
 
6 (CH2)3N(CH3)2 20.4 ± 3.6 — 85.8 ± 0.5 0.865 ± 0.011 
7 
 
57.3 ± 0.4 
10.020 ± 
0.604 
91.1 ± 0.8 0.929 ± 0.016 
8 
 
33.5 ± 1.6 — 66.0 ± 3.4 4.442 ± 0.049 
9 
 
58.1 ± 4.1 6.546 ± 0.177 76.4 ± 0.2 3.034 ± 0.072 
10 
 
49.6 ± 1.3 9.410 ± 0.489 71.9 ± 4.3 3.666 ± 0.054 
isomer 2,7-
diaza
 
11 
 
20.1 ± 1.4 — 20.7 ± 0.9 — 
12 
 
20.3 ± 1.0 — 31.4 ± 1.7 — 
13 
 
51.6 ± 3.2 
11.330 ± 
0.464 
37.6 ± 1.6 — 
isomer 3,6-
diaza
 
14 
 
7.7 ± 2.1 — 20.4 ± 1.9 — 
15 
 
10.1 ± 3.1 — 17.2 ± 7.3 — 
16 
 
21.9 ± 5.7 — 58.5 ± 9.0 10.380 ± 0.308 
17 
 
33.0 ± 4.5 — 16.1 ± 0.7 — 
18 
 
72.2 ± 0.7 4.263 ± 0.078 30.5 ± 5.7 — 
N-substituted 9-fluoroquinobenzothiazines 
 
  
19 H 6.6 ± 1.3 — 81.0 ± 1.4 1.020 ± 0.028 
20 CH3 3.0 ± 1.6 — 35.3 ± 12.3 — 
21 (CH2)3NH2 6.5 ± 2.8 — 76.3 ± 1.2 2.511 ± 0.047 
22 (CH2)4NH2 2.3 ± 2.1 — 64.7 ± 1.0 3.929 ± 0.196 
23 
 
27.0 ± 2.8 — 97.7 ± 0.5 0.463 ± 0.010 
1
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Table 1. Cont.
Compound R
%
Inhibition
+/− 6 a
IC50 eeAChE
b [µM] +/−
SEM c
%
Inhibition
+/− 6
IC50 eqBuChE
d [µM] +/−
SEM
N-substituted 9-fluoroquinobenzothiazines
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isomer 1,6-
diaza
 
1 
 
45.4 ± 9.8 — 65.4 ± 3.0 5.748 ± 0.164 
2 
 
60.3 ± 8.8 8.309 ± 0.315 56.6 ± 2.4 8.942 ± 0.239 
3 13.7 ± 1.5 — 63.6 ± 2.4 9.250 ± 0.275 
4 
 
22.4 ± 1.1 — 57.0 ± 7.4 9.493 ± 0.330 
5 
 
7.3 ± 0.9 — 52.5 ± 5.9 10.080 ± 0.441 
isomer 1,8-
diaza
 
6 (CH2)3N(CH3)2 20.4 ± 3.6 — 85.8 ± 0.5 0.865 ± 0.011 
7 
 
57.3 ± 0.4 
10.020 ± 
0.604 
91.1 ± 0.8 0.929 ± 0.016 
8 
 
33.5 ± 1.6 — 66.0 ± 3.4 4.442 ± 0.049 
9 
 
58.1 ± 4.1 6.546 ± 0.177 76.4 ± 0.2 3.034 ± 0.072 
10 
 
49.6 ± 1.3 9.410 ± 0.489 71.9 ± 4.3 3.666 ± 0.054 
isomer 2,7-
diaza
 
11 
 
20.1 ± 1.4 — 20.7 ± 0.9 — 
12 
 
20.3 ± 1.0 — 31.4 ± 1.7 — 
13 
 
51.6 ± 3.2 
11.330 ± 
0.464 
37.6 ± 1.6 — 
isomer 3,6-
diaza
 
14 
 
7.7 ± 2.1 — 20.4 ± 1.9 — 
15 
 
10.1 ± 3.1 — 17.2 ± 7.3 — 
16 
 
21.9 ± 5.7 — 58.5 ± 9.0 10.380 ± 0.308 
17 
 
33.0 ± 4.5 — 16.1 ± 0.7 — 
18 
 
72.2 ± 0.7 4.263 ± 0.078 30.5 ± 5.7 — 
N-substituted 9-fluoroquinobenzothiazines 
 
  
19 H 6.6 ± 1.3 — 81.0 ± 1.4 1.020 ± 0.028 
20 CH3 3.0 ± 1.6 — 35.3 ± 12.3 — 
21 (CH2)3NH2 6.5 ± 2.8 — 76.3 ± 1.2 2.511 ± 0.047 
22 (CH2)4NH2 2.3 ± 2.1 — 64.7 ± 1.0 3.929 ± 0.196 
23 
 
27.0 ± 2.8 — 97.7 ± 0.5 0.463 ± 0.010 
19 H 6.6 ± 1.3 — 81.0 ± 1.4 1.020 ± 0.028
20 CH3 3.0 ± 1.6 — 35.3 ± 12.3 —
21 (CH2)3NH2 6.5 ± .8 76.3 ± 1.2 2.511 ± 0.047
22 (CH2)4NH2 2.3 ± 2.1 — 64.7 ± 1.0 3.929 ± 0.196
23
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19  6.6  1.3  81.0 ± 1.4 1.020 ± 0.028 
20 CH3 3.0 ± 1.6 — 35.3 ± 12.3 — 
21 (CH2)3NH2 6.5 ± 2.8 — 76.3 ± 1.2 2.511 ± 0.047 
22 (CH2)4NH2 2.3 ± 2.1 — 64.7 ± 1.0 3.929 ± 0.196 
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N-substituted 9- ethylthioquinobenzothiazines 
 
 
24 
 
83.4 ± 1.1 0.784 ± 0.018 95.5 ± 0.8 0.535 ± 0.013 
25 
 
78.0 ± 1.4 2.218 ± 0.062 99.9 ± 0.7 0.506 ± 0.014 
Reference 
Tacrine    0.024 ± 0.001  0.002 ± 0.0005 
a% of inhibition at 10 μM compound concentration; values are expressed as mean ± standard deviation 
(Ϭ); bacetylcholinesterase from electric eel; cIC50 values, expressed as mean ± standard error of the mean 
(SEM) of at least three experiments; dbutyrylcholinesterase form equine serum. 
All the tested compounds displayed inhibitory activity against both cholinesterases at a 
concentration of 10 μM during screening; however, their activity was relatively higher against 
eqBuChE. The IC50 values were determined for those compounds that had an inhibitory potency of 
greater than 50% (seven compounds in the case of eeAChE and 17 compounds in the case of eqBuChE). 
The results obtained revealed that among the tested compounds, there were seven nonselective 
inhibitors of both enzymes, two selective inhibitors of eeAChE, and nine selective inhibitors of 
eqBuChE. Their potencies against eeAChE were in a submicromolar-to-micromolar range with IC50 
values of 0.78–11.33 μM, while their IC values against eqBuChE ranged from 0.46 to 10.38 μM. Such 
an inhibitory activity is characteristic of moderate or weak cholinesterase inhibitors. The most potent 
among the tested compounds were the tetracyclic ones, N-substituted derivatives of 
quinobenzothiazine (24 and 25) with closely related structures (N,N-diethylaminobutynyl and N-
pyrrolidinobutynyl substituents, respectively), which inhibited both enzymes. On the other hand, N-
substituted 9-fluoroquinobenzothiazine derivatives were found to act as selective inhibitors of 
eqBuChE, and among them, the most potent was compound 23 which showed an IC50 value of 0.46 
μM. Since the subseries of tricyclic derivatives contain different substituents, the classical analysis of 
structure–activity relationships could not be performed; however, several relationships were 
observed to some extent. Among the tricyclic compounds tested, 1,6-diaza-isomers were found to be 
selective inhibitors of eqBuChE, except for one nonselective inhibitor (compound 2). On the other 
hand, among 1,8-diaza-isomers, only one compound (compound 6) was identified as a selective 
inhibitor of eqBuChE (IC50 = 0.87 μM), while the remaining compounds were nonselective inhibitors. 
The amino substituent was observed to have an influence on the potency of 2,7-diaza-isomers. For 
instance, the exchange of diethyl group with cyclic pyrrolidine substituent allowed the inhibitory 
potency of compound 13 to remain in the same range, while the introduction of piperidine ring 
improved its potency. Derivatives of 3,6-diaza-isomers were found to be rather weak inhibitors, with 
an exception of compound 18. In summary, among the tested compounds, the most potent selective 
inhibitor of eqBuChE was compound 23, and the most potent nonselective inhibitor of both enzymes 
was compound 24. 
The next step of the study was to determine the type of inhibition exhibited by the selected 
compound 24 which showed a good inhibitory activity against both cholinesterases. This was carried 
out by making use of the calculated values of Vmax and Km of the Michaelis–Menten kinetics and 
further through analyzing the Lineweaver–Burk and Cornish-Bowden reciprocal plots. Figures 2–5 
present the graphs that illustrate the type of inhibition exhibited by compound 24. It can be 
understood that the compound displayed a noncompetitive type of inhibition against both enzymes. 
24
Molecules 2020, 25, 2604 5 of 13 
 
N-substituted 9-methylthioquinobenzothiazines 
 
 
24 
 
83.4 ± 1.1 0.784 ± 0.018 95.5 ± 0.8 0.535 ± 0.013 
25 
 
78.0 ± 1.4 2.218 ± 0.062 99.9 ± 0.7 0.506 ± 0.014 
Reference 
Tacrine    0.024 ± 0.001  0.002 ± 0.0005 
a% of inhibition at 10 μM compound concentration; values are expressed as mean ± standard deviation 
(Ϭ); bacetylcholinesterase from electric eel; cIC50 values, expressed as mean ± standard error of the mean 
(SEM) of at least three experiments; dbutyrylcholinesterase form equine serum. 
All the tested compounds displayed inhibitory activity against both cholinesterases at a 
concentration of 10 μM during screening; however, their activity was relatively higher against 
eqBuChE. The IC50 values were determined for those compounds that had an inhibitory potency of 
greater than 50% (seven compounds in the case of eeAChE and 17 compounds in the case of eqBuChE). 
The results obtained revealed that among the tested compounds, there were seven nonselective 
inhibitors of both enzymes, two selective inhibitors of eeAChE, and nine selective inhibitors of 
eqBuChE. Their potencies against eeAChE were in a submicromolar-to-micromolar range with IC50 
values of 0.78–11.33 μM, while their IC values against eqBuChE ranged from 0.46 to 10.38 μM. Such 
an inhibitory activity is characteristic of moderate or weak cholinesterase inhibitors. The most potent 
among the tested compounds were the tetracyclic ones, N-substituted derivatives of 
quinobenzothiazine (24 and 25) with closely related structures (N,N-diethylaminobutynyl and N-
pyrrolidinobutynyl substituents, respectively), which inhibited both enzymes. On the other hand, N-
substituted 9-fluoroquinobenzothiazine derivatives were found to act as selective inhibitors of 
eqBuChE, and among them, the most potent was compound 23 which showed an IC50 value of 0.46 
μM. Since the subseries of tricyclic derivatives contain different substituents, the classical analysis of 
structure–activity relationships could not be performed; however, several relationships were 
observed to some extent. Among the tricyclic compounds tested, 1,6-diaza-isomers were found to be 
selective inhibitors of eqBuChE, except for one nonselective inhibitor (compound 2). On the other 
hand, among 1,8-diaza-isomers, only one compound (compound 6) was identified as a selective 
inhibitor of eqBuChE (IC50 = 0.87 μM), while the remaining compounds were nonselective inhibitors. 
The amino substituent was observed to have an influence on the potency of 2,7-diaza-isomers. For 
instance, the exchange of diethyl group with cyclic pyrrolidine substituent allowed the inhibitory 
potency of compound 13 to remain in the same range, while the introduction of piperidine ring 
improved its potency. Derivatives of 3,6-diaza-isomers were found to be rather weak inhibitors, with 
an exception of compound 18. In summary, among the tested compounds, the most potent selective 
inhibitor of eqBuChE was compound 23, and the most potent nonselective inhibitor of both enzymes 
was compound 24. 
The next step of the study was to determine the type of inhibition exhibited by the selected 
compound 24 which showed a good inhibitory activity against both cholinesterases. This was carried 
out by making use of the calculated values of Vmax and Km of the Michaelis–Menten kinetics and 
further through analyzing the Lineweaver–Burk and Cornish-Bowden reciprocal plots. Figures 2–5 
present the graphs that illustrate the type of inhibition exhibited by compound 24. It can be 
understood that the compound displayed a noncompetitive type of inhibition against both enzymes. 
83.4 ± . 0.784 ± 0.018 95.5 ± 0.8 0. 35 ± 0.013
25
Molecules 20 , 25, 2604 5 of 13 
 
N-substituted 9-methylthioquinobenzothiazines 
 
 
 
 
83.4 ± 1.  0.784 ± 0. 18 95.  ± 0.8 0.53  ± 0. 13 
25 
 
78.0 ± 1.4 2. 18 ± 0. 62 99.  ± 0.7 0.506 ± 0. 14 
Ref r nce 
Tacrine    0. 24 ± 0. 01  0. 02 ± 0. 0 5 
a% of inhibition at 10 μM compound concentration; values are expressed as mean ± standard eviation 
(Ϭ); bacetylcholinesterase from electric eel; cIC50 values, expressed as mean ± standard error of the mean 
(SEM) of at least three xperiments; dbutyr lcholinesterase form equine serum. 
All the tested compounds displayed inhibitory activity against both cholinesterase  at a 
concentration of 10 μM during screeni g; however, their activity was relatively higher against 
eqBuChE. The IC50 values wer  det rmined for those compounds that had an inhibitory potency of 
greater than 50% (seven compounds in the case of eeAChE and 17 compounds in the case of eqBuChE). 
The results obtained revealed that among the tested compounds, ther  wer  seven nonsel ctive 
inhibitors of both enzymes, two sel ctive inhibitors of eeAChE, and ni e sel ctive inhibitors of 
eqBuChE. Their potencies against eeAChE wer  in a submicromolar-to-micromolar ange with IC50 
values of 0.78–11.33 μM, while their IC values against eqBuChE ranged from 0.46 to 10.38 μM. Such 
an inhibitory activity is char cteristic of moderate or weak cholinesterase inhibitors. The most potent 
among the tested compounds wer  the tetracyclic ones, N-substituted derivatives of 
quinobenzothiazine (24 and 25) with closely related structures (N,N-diethylaminobutynyl and N-
pyrrolidinobutynyl substituents, respectively), which inhibited both enzymes. On the other hand, N-
substituted 9-fluor quinobenzothiazine derivatives wer  found to act as sel ctive inhibitors of 
eqBuChE, and among them, the most potent was compound 23 which showed an IC50 value of 0.46 
μM. Since the subseries of tricyclic derivatives contain differ nt substituents, the classical analysi  of 
structure–activity relationships could not be performed; however, several relationships wer  
observed to some xtent. Among the tricyclic ompounds tested, 1,6-diaza-isomers wer  found to be 
sel ctive inhibitors of eqBuChE, except for one nonsel ctive inhibitor (compound 2). On the other 
hand, among 1,8-diaza-isomers, only one compound (compound 6) was identified as a sel ctive 
inhibitor of eqBuChE (IC50 = 0.87 μM), while the remaini g compounds wer  nonsel ctive inhibitors. 
The amino substituent was observed to have an influence on the potency of 2,7-diaza-isomers. For 
instance, the xchange of diethyl group with cyclic pyrrolidine substituent allowed the inhibitory 
potency of compound 13 to remain in the same range, while the introduction of pi eridine ring 
improved its potency. Derivatives of 3,6-diaza-isomers wer  found to be rather weak inhibitors, with 
an exception of compound 18. In sum ary, among the tested compounds, the most potent sel ctive 
inhibitor of eqBuChE was compound 23, and the most potent nonsel ctive inhibitor of both enzymes 
was compound 24. 
The next step of the study was to det rmine the type of inhibition exhibited by the sel cted 
compound 24 which showed a good inhibitory activity against both cholinesterase . This was carried 
out by making use of the calculated values of Vmax and Km of the Michaelis–Menten kinetics and 
further through analyzing the Lineweaver–Burk and Cornish-Bowden reciprocal plots. Figures 2–5 
pres nt the graphs that illustrate the type of inhibition exhibited by compound 24. It can be 
understood that the compound isplayed a noncompetitive type of inhibition against both enzymes. 
78.0 ± 1.4 2.218 ± 0.062 99.9 ± 0.7 0.506 ± 0.014
Reference
Tacrine 0.024 ± 0.001 0.002 ± 0.0005
a % of inhibition at 10 µ co pound concentration; values are expres ed as ean st e i ti (6);
b acetylcholinesterase from electric eel; c IC50 values, expressed as mean ± standard error of the mean (SEM) of at
least thre experiments; d butyrylcholinest rase form equine se um.
All the tested co s isplayed inhibitory activity against bot cholinesterases at a
concentration of 10 µ creening; however, their activity was relatively higher against
eqBuChE. The I 50 alues were d termined for those compounds that had an inhibitory p tency
of greater than 50% (seven c mpounds in the case of eeAChE and 17 compounds in the case of
eqBuChE). The results obtained revealed that among the tested compounds, there were seven
nonselective inhibitors of both enzymes, two selective inhibitors of eeAChE, and nine selective
inhibitors of eqBuChE. Their potencies against eeAChE were in a submicro olar-to-micromolar range
with IC50 values of 0.78–11.33 µM, while their IC50 v lues against eqBuChE rang d from 0.46 to
10.38 µM. Such an inhibit ry activity is characteris i of moderate or weak cholinesterase inhibitors.
The m st potent mong the tested comp unds were the tetracyclic on s, N-substi uted derivatives
of quin benzo hiazine (24 a d 25) wi h closely related structur s (N,N-diethylaminobutynyl and
N-pyrrolidinobutynyl substituents, respectively), which inhibited both enzymes. O the ther hand,
N-substituted 9-fluoroquinobenzothiazine derivatives were found to act as selective inhibitors of
eqBuChE, and among them, the most potent was compound 23 which showed an IC50 value of 0.46 µM.
Since the subseries of ricyclic derivatives contain different substitu nts, th classical analysis of
structure–activity r lationships could not be performe ; however, several relationships were bserved
to some extent. Among the tricycli compounds te ted, 1,6-diaza-isomers were found to be selective
inhibitors of eqBuChE, except for one nonselective inhibitor (compound 2). On the other hand,
among 1,8-diaza-isomers, only one compound (compound 6) was identified as a selective inhibitor of
eqBuChE (IC50 = 0.87 µM), while the remaining compounds were nonselective inhibitors. The amino
substituent was observed to have a i flu nce on the potency of 2,7- iaza-is mers. For instance,
the exchange of diethyl group with cyclic pyrr lidine substit ent allowed th inhibitory potency of
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compound 13 to remain in the same range, while the introduction of piperidine ring improved its
potency. Derivatives of 3,6-diaza-isomers were found to be rather weak inhibitors, with an exception
of compound 18. In summary, among the tested compounds, the most potent selective inhibitor
of eqBuChE was compound 23, and the most potent nonselective inhibitor of both enzymes was
compound 24.
The next step of the study was to determine the type of inhibition exhibited by the selected
compound 24 which showed a good inhibitory activity against both cholinesterases. This was carried
out by making use of the calculated values of Vmax and Km of the Michaelis–Menten kinetics and
further through analyzing the Lineweaver–Burk and Cornish-Bowden reciprocal plots. Figures 2–5
present the graphs that illustrate the type of inhibition exhibited by compound 24. It can be understood
that the compound displayed a noncompetitive type of inhibition against both enzymes.
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Figure 2. Lineweaver–Burk plot illustrating a noncompetitive type of eeAChE inhibition by 
compound 24. S = acetylthiocholine; V = initial velocity rate. 
 
Figure 3. Cornish-Bowden plot illustrating a noncompetitive type of eeAChE inhibition by compound 
24. S = acetylthiocholine; V = initial velocity rate; I = inhibitor concentration. 
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Figure 2. Lineweaver–Burk plot illustrating a noncompetitive type of eeAChE inhibition by compound
24. S = acetylthiocholine; V = initial velocity rate.
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Figure 4. Lineweaver–Burk plot illustrating a noncompetitive type of eqBuChE inhibition by
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Figure 5. Cornish-Bowden plot illustrating a noncompetitive type of eqBuChE inhibition by compound
24. S = butyrylthiocholine; V = initial velocity rate; I = inhibitor concentration.
The results obtained from in silico studies allow explaining the differences observed in the activity
of the compounds to a certain extent. The most active inhibitor of AChE (compound 24, Figure 6) also
turned out to be the ligand that was rated the highest during screening against that enzyme.
Similar to tacrine, the tetracyclic system forms “sandwich-like” π–π nteractions with TRP84 and
PHE330, w ich were ad itionally reinforced by surrounding aromatic residues suc as TYR334, TYR442,
and TRP432. We observed similar nteractions in docking results for all the tetracyclic compounds,
but the example of compound 19 showed that these interactions are not enough for effective inhibition
of the enzyme. The large and stiff aminobutynyl substituents directed to peripheral anionic site (PAS)
were crucial for enhancing the inhibitory potential. In the cases of both quinobenzothiazine derivatives
with N-substituted aminobutynyl moieties (24 and 25), tertiary amine was placed near TYR70, TYR121,
and TRP279 where it can participate in the cation–π interactions. In all diazaphenothiazines with
similar substituents, we observed the formation of cation–π interactions with TRP84 and PHE330.
The diazaphenothiazine group was mostly directed toward the space above the oxyanion hole where
we did not find its participation in either a strong or a specific interaction.
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As the docking results indicated a mor extensive ctive site for BuChE, we b erved a much larger
variation in the arrangement of ligands. Again, the m st potent inhibitors w re present among the
top-scored compounds. In the case of most potent inhibitors among quinobenzothiazine derivatives,
three aromatic residues (TRP82, TRP231, and PHE329) seemed to play a key role in the binding
process. In this group of ligands, we most often observed CH–π interactions with TRP231 and cation–π
interactions with TRP82 or PHE329. The distance between the tetracyclic moiety and the protonated
nitrogen was crucial for inhibition potency of the compounds. The optimal distance in compound 23
(presented in Figure 7) allowed the abovementioned cation–π interaction to occur with both TRP82 and
PHE329. In the case of diazaphenothiazine derivatives, we observed conformations interacting with
the same aromatic amin acids as in the quinob nzothiazi e derivatives. The differ nc s observed in
activity between parti ular isomers can be linked to the influence of the position of the nitrogen atom
in the pyridine system on the strength of CH–π interactions.Molecules 2020, 25, 2604 9 of 13 
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3. Methods
3.1. Chemistry
The standard NMR spectra were recorded on a Bruker Avance spectrometer (1H at 600 MHz,
13C at 150 MHz, Bruker, Billerica, MA, USA) in CDCl3. Fast atom bombardment mass spectra (FAB
MS, in glycerol) were performed on a Finnigan MAT 95 spectrometer (Thermo Finnigan LLC, San Jose,
CA, USA) at 70 eV.
Most compounds tested in the study were synthesized according to the previously described
procedures: 4 and 5 [33]; 6 and 8–10 [34]; 7 and 11–13 [35]; 14–16 [32]; 17 and 18 [36]; 19 [40]; 20–23 [31];
and 24 and 25 [30]. Compounds 1–3 were synthesized according to Scheme 1 as follows.
A mixture of 10-propargyl-1,6-diazaphenothiazine (120.5 mg, 0.5 mmol), paraformaldehyde (50 mg,
0.5 mmol), amine (0.7 mmol), and cuprous chloride (catalytic amount) in peroxide-free, dry 1,4-dioxane
(10 mL) was heated with continuous stirring at 70 ◦C for 3 h. After cooling (20 mL) water was added
and the mixture was extracted with chloroform (50 mL), dried with Na2SO4, and evaporated in vacuo.
The dry residue was dissolved in CHCl3 and purified by column chromatography (aluminium oxide,
CHCl3) to obtain compounds 1–3.
3.1.1. 10-(4-Pyrrolidin-1-yl-but-2-ynyl)-1,6-diazaphenothiazine (1)
(0.121 g, 76%); an oil. 1H NMR (CDCl3) δ: 1.761–.79 (m, 4H, 2CH2), 2.552–.57 (m, 4H, 2CH2),
3.41 (s, 2H, CH2) 4.71 (s, 2H, CH2), 6.83 (dd, J = 7.2 Hz, J = 4.8 Hz, 1H, H3), 7.04 (d, J = 7.8 Hz, 1H, H9),
7.307–.34 (m, 2H H8, H4), 8.018–.05 (m, 2H, H2, H7). 13C NMR (CDCl3) δ: 23.77, 35.17, 43.32, 52.60,
79.18, 80.32, 116.28, 118.51,121.24, 121.87, 134.56, 137.90, 142.96, 144.51, 145.22, 151.97. FAB MS m/z:
322 (M, 80), 252 (M+1-C4H8N, 100). TLC Anal.: (aluminum oxide 60F254 neutral, CHCl3) Rf = 0.33.
Anal. Calcd for: C18H18N4S C, 67.05, H 5.63, N 17.38. Found: C, 66.84, H 5.58, N 17.11.
3.1.2. 10-(4-Piperidin-1-yl-but-2-ynyl)- 1,6-diazaphenothiazine (2)
(0.124 g, 74%); an oil. 1H NMR (CDCl3) δ: 1.401–.42 (m, 2H, CH2), 1.591–.61 (m, 4H, 2CH2),
2.462–.48 (m, 4H, 2CH2), 3.28 (s, 2H, CH2), 4.72 (s, 2H, CH2), 6.79 (dd, J = 7.2 Hz, J = 4.8 Hz, 1H, H3),
7.05 (d, J = 7.8 Hz, 1H, H9), 7.317–.34 (m, 2H H8, H4), 8.028–.04 (m, 2H, H2, H7). 13C NMR (CDCl3)
δ: 23.83, 25.75, 35.17, 53.27, 79.80, 80.10, 116.28, 118.51,121.33, 121.86, 134.57, 134.63, 137.90, 142.95,
144.50, 145.22, 151.98. FAB MS m/z: 337 (M, 70), 201 (M+1-C5H10N, 100). TLC Anal.: (aluminum oxide
60F254 neutral, CHCl3) Rf = 0.41. Anal. Calcd for: C19H20N4S C, 67.83, H 5.99, N 16.65. Found: C,
67.59, H 5.91, N 16.40.
3.1.3. 10-(4-Morpholin-4-yl-but-2-ynyl)-1,6-diazaphenothiazine (3)
(0.115 g, 68%); an oil. 1H NMR (CDCl3) δ: 1.71–.78 (m, 2H, CH2), 2.552–.58 (m, 2H, CH2), 3.403–.43
(m, 4H, 2CH2), 4.71 (s, 2H, CH2), 6.78 (dd, J = 7.2 Hz, J = 4.8 Hz, 1H, H3), 7.05 (d, J = 7.8 Hz, 1H, H9),
7.287–.31 (m, 2H, H8, H4), 8.018–.05 (m, 2H, H2, H7). 13C NMR (CDCl3) δ: 23.81, 35.20, 43.41, 52.63,
79.18, 80.37, 116.28, 118.51,121.24, 121.87, 134.56, 137.90, 142.96, 144.51, 145.22, 151.97.FAB MS m/z: 339
(M+1, 40), 201 (M+1-C8H12NO, 60). TLC Anal.: (aluminum oxide 60F254 neutral, CHCl3) Rf = 0.38.
Anal. Calcd for: C18H18N4SO C 63.88, H 5.36, N 16.56. Found: C 63.68, H 5.31, N 16.44.
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3.2. Molecular Modeling 
The three-dimensional structure of potential cholinesterase inhibitors (120 ligands) was drawn 
in Corina on-line (Molecular Networks and Altamira) [41]. Atom types were checked, hydrogen 
atoms were added, and Gasteiger–Marsili charges were assigned with Sybyl X 2.1 (Tripos, Certara, 
Princeton, NJ, USA) [42]. AChE and BuChE were prepared from the crystal structures of 2CKM and 
1P0I, respectively, before virtual screening in Hermes (CCDC). Histidine residues were protonated 
at Nε, and hydrogen atoms were added. Water molecules and ligands were removed from the 2CKM 
complex, whereas in 1P0I, 24 water molecules were saved using toggle option thereby allowing the 
program to decide to use them in calculations. Docking was performed with GoldSuite 5.1 (CCDC) 
[43]. We defined binding sites as all amino acid residues present within a radius of 10 Å from bis-(7)-
tacrine in the case of AChE and 20 Å from the glycerol molecule in the case of BuChE. The genetic 
algorithm was started with automatic settings for flexible ligands. As a result, we obtained three top-
scored ligand poses per compound, which were sorted by GoldScore and ChemScore function values 
for AChE and BuChE, respectively. The results were visualized using PyMol 0.99rc6 [44]. The whole 
procedure was already described and validated [38]. 
3.3. Biological Tests 
3.3.1. AChE/BuChE-Inhibitory Activity 
The following reagents were purchased from Sigma–Aldrich (Steinheim, Germany): 5,5′-
dithiobis-(2-nitrobenzoic acid) (DNTB), acetylthiocholine iodide (ATC), butyrylthiocholine iodide 
(BTC), AChE from Electrophorus electricus, and BuChE from horse serum. The enzymes were prepared 
as aqueous stock solutions with a concentration of 5 U/mL. Before use, they were diluted to a final 
concentration of 3.125 U/mL. In addition, solutions of 0.0125 M DTNB, 0.01875 M ATC, and 0.01875 
M BTC, as well as 0.1 M phosphate buffer (pH 8.0), were prepared in water. The biological assay was 
performed using Ellman’s method [39] which was modified for 24-well plates. For this assay, 25 μL 
of the tested compounds or water (in the blank samples) and 20 μL of the enzyme in 765 μL of the 
buffer were incubated for 5 min at 25 °C before starting the reaction. Then, 20 μL of DTNB and 20 μL 
of the ATC/BTC solutions were added. After 5 min, the changes in absorbance were measured at 412 
nm using an EnSpire multimode microplate reader (PerkinElmer, Waltham, MA, USA). All the 
compounds were tested at a screening concentration of 10 μM. For determining the enzyme 
inhibition, the following formula was used: 100 − (S/B) × 100, where S and B were the activities of the 
Sche e 1. Synthesis of dipyridothiazines 1–3.
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3.2. Molecular Modeling
The three-dimensional structure of potential cholinesterase inhibitors (120 ligands) was drawn
in Corina on-line (Molecular Networks and Altamira) [41]. Atom types were checked, hydrogen
atoms were added, and Gasteiger–Marsili charges were assigned with Sybyl X 2.1 (Tripos, Certara,
Princeton, NJ, USA) [42]. AChE and BuChE were prepared from the crystal structures of 2CKM and
1P0I, respectively, before virtual screening in Hermes (CCDC). Histidine residues were protonated at
Nε, and hydrogen atoms were added. Water molecules and ligands were removed from the 2CKM
complex, whereas in 1P0I, 24 water molecules were saved using toggle option thereby allowing the
program to decide to use them in calculations. Docking was performed with GoldSuite 5.1 (CCDC) [43].
We defined binding sites as all amino acid residues present within a radius of 10 Å from bis-(7)-tacrine
in the case of AChE and 20 Å from the glycerol molecule in the case of BuChE. The genetic algorithm
was started with automatic settings for flexible ligands. As a result, we obtained three top-scored
ligand poses per compound, which were sorted by GoldScore and ChemScore function values for
AChE and BuChE, respectively. The results were visualized using PyMol 0.99rc6 [44]. The whole
procedure was already described and validated [38].
3.3. Biological Tests
3.3.1. AChE/BuChE-Inhibitory Activity
The following reagents were purchased from Sigma–Aldrich (Steinheim, Germany): 5,5′-dithiobis-
(2-nitrobenzoic acid) (DNTB), acetylthiocholine iodide (ATC), butyrylthiocholine iodide (BTC),
AChE from Electrophorus electricus, and BuChE from horse serum. The enzymes were prepared
as aqueous stock solutions with a concentration of 5 U/mL. Before use, they were diluted to a final
concentration of 3.125 U/mL. In addition, solutions of 0.0125 M DTNB, 0.01875 M ATC, and 0.01875 M
BTC, as well as 0.1 M phosphate buffer (pH 8.0), were prepared in water. The biological assay was
performed using Ellman’s method [39] which was modified for 24-well plates. For this assay, 25 µL
of the tested compounds or water (in the blank samples) and 20 µL of the enzyme in 765 µL of the
buffer were incubated for 5 min at 25 ◦C before starting the reaction. Then, 20 µL of DTNB and 20 µL
of the ATC/BTC solutions were added. After 5 min, the changes in absorbance were measured at
412 nm using an EnSpire multimode microplate reader (PerkinElmer, Waltham, MA, USA). All the
compounds were tested at a screening concentration of 10 µM. For determining the enzyme inhibition,
the following formula was used: 100 − (S/B) × 100, where S and B were the activities of the respective
enzymes with and without the test sample, respectively. IC50 values were determined for compounds
that showed greater than 50% inhibitory activity at the screening concentration. To determine the IC50
value, the absorbance measured at six different concentrations of the inhibitor was converted to %
inhibition of the enzyme and plotted against the applied concentration of the inhibitor, using nonlinear
regression (GraphPad Prism 5; GraphPad Software, San Diego, CA, USA). Tacrine was used as a
reference compound for the assay. All the reactions were performed in triplicate. Data are expressed as
the mean ± SEM.
3.3.2. Kinetic Studies
Kinetic studies were carried out by following Ellman’s method [39] modified for 96-well plates,
using different concentrations of the substrate. The stock solutions of ATC and BTC (0.02125 M) were
prepared in water and diluted before use. The aqueous stock solutions of enzymes (5 U/mL) were
diluted to a final concentration of 0.384 U/mL. For each concentration of the test compounds, ATC or
BTC was used at a concentration of 0.3, 0.24, 0.18, 0.12, 0.06, and 0.04 mM in the wells. Lineweaver–Burk
and Cornish-Bowden plots were generated using linear regression in GraphPad Prism 5 (GraphPad
Software, San Diego, CA, USA). Each experiment was performed in triplicate.
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4. Conclusions
The in silico and in vitro tests performed in this study led to the identification of cholinesterase
inhibitors among dipyridothiazine and quinobenzothiazine derivatives. Compounds with dual
antitumor and cholinesterase-inhibitory properties can be useful both in the treatment of cancer and
AD prevention [45]. Such a conclusion can be drawn based on the literature reports indicating a
lower incidence of AD among people who have previously received chemotherapy. In the case of AD,
neuropathological changes, including loss of cholinergic neurons and the formation of Aβ plaques
and NFTs, which lead to the development of disease symptoms, probably appear several years earlier.
Hence, disease treatment may begin too late and it may be difficult to find an effective AD therapy
because no prophylactic drugs have been used before the onset of symptoms. It can, therefore, be
assumed that some anticancer drugs may exert a preventive effect by inhibiting the neurodegenerative
processes at an earlier stage of disease development. Dual antitumor and cholinesterase-inhibitory
activity can be considered as a valuable combination for the treatment of both cancer and AD. Such dual
properties are found in the compounds described herein, and the results of this study might open new
directions of research on the group of tricyclic phenothiazine derivatives.
Supplementary Materials: The following are available online. Table S1. Structures of tested compounds.
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